These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 32428508)

  • 1. Mortality Risk Prediction in Amyopathic Dermatomyositis Associated With Interstitial Lung Disease: The FLAIR Model.
    Lian X; Zou J; Guo Q; Chen S; Lu L; Wang R; Zhou M; Fu Q; Ye Y; Bao C
    Chest; 2020 Oct; 158(4):1535-1545. PubMed ID: 32428508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic analysis of MDA5-associated clinically amyopathic dermatomyositis with interstitial lung disease.
    Wang W; Sun X; Xu Y; Tan W; Liu Y; Zhou J
    Immun Inflamm Dis; 2024 Jun; 12(6):e1332. PubMed ID: 38934403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
    J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients.
    Zou J; Guo Q; Chi J; Wu H; Bao C
    Clin Rheumatol; 2015 Apr; 34(4):707-14. PubMed ID: 25609178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.
    Jiang L; Wang Y; Peng Q; Shu X; Wang G; Wu X
    Clin Rheumatol; 2019 Jun; 38(6):1655-1663. PubMed ID: 30739212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease.
    Nara M; Komatsuda A; Omokawa A; Togashi M; Okuyama S; Sawada K; Wakui H
    Mod Rheumatol; 2014 Jul; 24(4):633-6. PubMed ID: 24252021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
    Ye Y; Fu Q; Wang R; Guo Q; Bao C
    J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment mortality risk prediction model in patients with polymyositis/dermatomyositis-associated interstitial lung disease.
    Gui X; Li W; Jiang H; Wang R; Yu M; Zhao T; Ma M; Ding J; Jin Z; Qiu Y; Qiu X; Zhang Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xin X; Xiao Y
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38663883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
    Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
    Arthritis Care Res (Hoboken); 2016 May; 68(5):689-94. PubMed ID: 26414240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and HRCT features of amyopathic dermatomyositis associated with interstitial lung disease: A retrospective study of 128 patients with connective tissue disease-related interstitial lung disease.
    Wu T; Zhou H; Xu S; Deng Z; Zhang Y; Ding Q
    Am J Med Sci; 2023 May; 365(5):429-436. PubMed ID: 36521530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiomics based on HRCT can predict RP-ILD and mortality in anti-MDA5 + dermatomyositis patients: a multi-center retrospective study.
    He W; Cui B; Chu Z; Chen X; Liu J; Pang X; Huang X; Yin H; Lin H; Peng L
    Respir Res; 2024 Jun; 25(1):252. PubMed ID: 38902680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease.
    Johnson C; Pinal-Fernandez I; Parikh R; Paik J; Albayda J; Mammen AL; Christopher-Stine L; Danoff S
    Lung; 2016 Oct; 194(5):733-7. PubMed ID: 27166633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble CXCL16 is a prognostic biomarker associated with rapidly progressive interstitial lung disease complicated with dermatomyositis.
    Li C; Han Y; Li X; Zhang H; Yao Z; Zhou J; Mu R; Zhao J
    Semin Arthritis Rheum; 2024 Aug; 67():152483. PubMed ID: 38843569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial lung diseases associated with amyopathic dermatomyositis.
    Suda T; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Naito T; Hashimoto D; Sato J; Toyoshima M; Hashizume H; Chida K
    Eur Respir J; 2006 Nov; 28(5):1005-12. PubMed ID: 16837503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease.
    Go DJ; Park JK; Kang EH; Kwon HM; Lee YJ; Song YW; Lee EB
    Rheumatol Int; 2016 Jan; 36(1):125-31. PubMed ID: 26223808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis.
    Kang EH; Lee EB; Shin KC; Im CH; Chung DH; Han SK; Song YW
    Rheumatology (Oxford); 2005 Oct; 44(10):1282-6. PubMed ID: 15972351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis.
    Takada T; Aoki A; Asakawa K; Sakagami T; Moriyama H; Narita I; Sato S
    Respir Med; 2015 Sep; 109(9):1174-80. PubMed ID: 26187000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
    Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T
    Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease.
    Gono T; Masui K; Nishina N; Kawaguchi Y; Kawakami A; Ikeda K; Kirino Y; Sugiyama Y; Tanino Y; Nunokawa T; Kaneko Y; Sato S; Asakawa K; Ukichi T; Kaieda S; Naniwa T; Okano Y; Kuwana M;
    Arthritis Rheumatol; 2021 Apr; 73(4):677-686. PubMed ID: 33118321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis.
    Ishikawa Y; Iwata S; Hanami K; Nawata A; Zhang M; Yamagata K; Hirata S; Sakata K; Todoroki Y; Nakano K; Nakayamada S; Satoh M; Tanaka Y
    Arthritis Res Ther; 2018 Oct; 20(1):240. PubMed ID: 30367666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.